Trial Profile

A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Samotolisib (Primary) ; Necitumumab
Indications Non-small cell lung cancer; Squamous cell cancer
Focus First in man; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

15 May 2018 Status changed to discontinued due to lack of activity as the observed DCR at 6 months is 4%, below the hypothesized 44% DCR at 6 months as the primary objective of this study.
26 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
26 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com